Fate Therapeutics
Fate Therapeutics' revenue fell 51.2% to $7 million in fiscal 2025. Its operating margin was −2,222.4%, down from −1,542.6% a year earlier. Free cash flow was −$112 million. The diluted share count rose 4.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Fate Therapeutics does
Fate Therapeutics is a San Diego drug developer working on cell therapies: treatments made from living immune cells that are engineered to attack disease. It has no approved products yet; all of its candidates are still in clinical trials or earlier testing.
Its approach starts from induced pluripotent stem cells (iPSCs), adult cells reprogrammed so they can grow without limit and turn into any cell type. Fate engineers these cells, builds a single master cell line from one clone, and uses it to make large batches of T cells or natural killer (NK) cells. Most cell therapies today are made one patient at a time from that patient's own cells; Fate's aim is a uniform, ready-made product that can be stored and given on demand.
Its lead candidate, FT819, is a CAR T-cell therapy (immune cells given a receptor that targets a marker on B cells) being tested in a Phase 1 trial for lupus in the United States, the United Kingdom and the European Union. It is also developing FT522, an NK cell candidate for autoimmune diseases, and FT825, a solid-tumor candidate it develops with Ono Pharmaceutical. Fate runs its own manufacturing plant in San Diego, and at the end of 2025 it had 161 full-time employees.
Its biggest risks, as it describes them
- Failing to finish development of, or win regulatory approval for, its cell therapy candidates.
- Its approach rests on new and unproven technology, so its candidates may never work as hoped.
- Delays in its clinical trials, including trouble enrolling patients or side effects in sick patients.
- It needs a lot more money to keep developing its candidates and expects to keep losing money.
- Problems at its own manufacturing plant or at the suppliers it relies on.
Income statement
Fate Therapeutics lost money in fiscal 2025: a net loss of $136 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 616 | 436 | 315 | 279 | 204 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
| Quick ratio | 7.8x | 4.4x | 8.5x | 7.6x | 5.8x |
Cash flow
Projections
Project Fate Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Fate Therapeutics shares on the open market, and 2 insiders sold $322,862.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Bahram ValamehrPresident and CEO, Director | Sold | 43,947 | $2.46 | $108,110 | Form 4 |
| Aug 4, 2026 | Cindy TahlSee Remarks | Sold | 38,800 | $2.46 | $95,448 | Form 4 |
| May 20, 2026 | Bahram ValamehrPresident and CEO, Director | Sold | 28,946 | $1.88 | $54,418 | Form 4 |
| May 20, 2026 | Cindy TahlSee Remarks | Sold | 25,590 | $1.88 | $48,109 | Form 4 |
| Jan 9, 2026 | Cindy TahlSee Remarks | Sold | 10,589 | $1.06 | $11,224 | Form 4 |
| Jan 9, 2026 | Bahram ValamehrPresident and CEO, Director | Sold | 5,190 | $1.07 | $5,553 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −251.9% | −985.3% | −1,737.0% |
| Altman Z'' | −3.74 | −7.03 | −13.30 |
| Accruals ratio | −4.7% | −13.4% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Fate Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics | FY25 | −51.2% | −2,222.4% | −1,685.8% | — | — | — | |
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | Compare |
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | Compare |
| Whitehawk Therapeutics | FY25 | −72.5% | −1,601.1% | −1,371.4% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4 | 4 | 5 | 11 | 31 | 56 | 96 | 64 | 14 | 7 |
| Revenue growth | 81.1% | −6.7% | 15.4% | 125.3% | 194.3% | 77.7% | 72.4% | −34.0% | −78.5% | −51.2% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 26 | 34 | 56 | 88 | 126 | 216 | 320 | 173 | 135 | 108 |
| Operating income | −32 | −42 | −67 | −101 | −128 | −217 | −308 | −190 | −210 | −148 |
| Net income | −34 | −43 | −67 | −98 | −173 | −212 | −282 | −161 | −186 | −136 |
| Diluted EPS (US$) | −1.05 | −1.02 | −1.19 | −1.44 | −2.10 | −2.24 | −2.91 | −1.64 | −1.64 | −1.15 |
| Diluted shares (millions) | 32 | 42 | 56 | 68 | 82 | 95 | 97 | 98 | 114 | 119 |
| Cash flow | ||||||||||
| Cash from operations | −30 | −37 | −39 | −83 | −39 | −163 | −248 | −132 | −123 | −106 |
| Capital expenditure | 0 | 2 | 2 | 7 | 5 | 51 | 36 | 6 | 1 | 6 |
| Free cash flow | −30 | −39 | −41 | −91 | −44 | −214 | −284 | −138 | −124 | −112 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 6 | 17 | 31 | 54 | 79 | 44 | 42 | 25 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 92 | — | 190 | 100 | 167 | 616 | 436 | 315 | 279 | 204 |
| Debt incl. finance leases | 13 | 19 | 18 | — | — | — | — | — | — | — |
| Total assets | 95 | 105 | 213 | 302 | 622 | 922 | 706 | 506 | 441 | 319 |
| Total liabilities | 22 | 28 | 53 | 58 | 238 | 243 | 222 | 138 | 122 | 112 |
| Shareholders' equity | 73 | 77 | 160 | 245 | 384 | 679 | 484 | 368 | 319 | 207 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −726.1% | −1,025.9% | −1,415.4% | −943.1% | −407.5% | −388.6% | −320.2% | −299.9% | −1,542.6% | −2,222.4% |
| Net margin | −760.1% | −1,046.1% | −1,405.0% | −919.0% | −551.6% | −379.9% | −292.6% | −253.3% | −1,366.5% | −2,051.1% |
| Free cash flow margin | −687.9% | −938.7% | −864.0% | −848.0% | −140.5% | −382.4% | −294.7% | −217.9% | −906.8% | −1,685.8% |
| Rule of 40 (growth + FCF margin) | −606.8% | −945.4% | −848.5% | −722.7% | 53.8% | −304.8% | −222.2% | −251.9% | −985.3% | −1,737.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −60.2% | −57.1% | −56.0% | −48.4% | −55.1% | −39.9% | −48.5% | −37.8% | −54.2% | −51.8% |
| Return on assets | −41.1% | −42.9% | −41.8% | −38.1% | −37.5% | −27.5% | −34.6% | −26.6% | −39.3% | −35.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |